By Josh Beckerman

Sesen Bio Inc. shares rose 23% to $4.97.

The company has said several times that it believes it is on track for a U.S. Food and Drug Administration decision on Vicineum by Aug. 18. A Biologics License Application for Vicineum for treatment of BCG-unresponsive non-muscle invasive bladder cancer is currently under Priority Review.

Sesen said early Wednesday that it was expanding its executive leadership team in support of its "continued transformation into a commercial-stage company."

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

August 12, 2021 15:16 ET (19:16 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Sesen Bio Charts.
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Sesen Bio Charts.